MedTrace Logo

Prevalence of Suicidal Risk in Psychiatric Settings

NCT07746193 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 262

Last updated 2026-08-04

No results posted yet for this study

Summary

France is among the countries with one of the highest suicide rates in the world, far ahead of its neighboring nations \[Wasserman et al., 2012\]. Suicide represents the second leading cause of death among 15-24-year-olds, just after road accidents, and the leading cause of death among 25-34-year-olds. In this context, a better utilization of all components of the healthcare system seems highly desirable, particularly through greater involvement of community psychiatrists in suicide prevention strategies. Approximately 25% of individuals who die by suicide have consulted a psychiatrist in the month preceding their death \[Luoma et al., 2002\], yet few data are available on this topic, especially regarding consultations with community psychiatrists outside of hospital settings.

Study objectives Main objective To assess the prevalence of suicidal risk during the 15 days preceding an outpatient psychiatric consultation in the Clermont-Ferrand area.

Main secondary objectives

* To describe the recruited population and potentially associated factors (age, sex, etc.).
* To assess the psychological pain of these individuals over the same period when suicidal thoughts are strongest, or, if absent, when they feel at their worst.
* To assess the self-esteem of these individuals over the same period when suicidal thoughts are strongest, or, if absent, when they feel at their worst.

Conditions

  • Psychiatric Disorder
  • Suicidal Crisis

Sponsors & Collaborators

  • University Hospital, Clermont-Ferrand

    lead OTHER

Principal Investigators

  • Pierre-Michel Llorca · CHU de Clermont-Fd

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2025-05-01
Completion
2025-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07746193 on ClinicalTrials.gov